Advertisement Covers CROI 2017


With Free Treatment for Citizens, but Not for Immigrants, Botswana Sees Progress, and Evidence of Why That Progress Has Stalled

February 14, 2017

On one hand, Botswana stands before the world, and certainly before its nearest neighbors as a model of determined and successful policies that confront one of the largest HIV burdens in the world. With possibly 22 percent of people there living with the virus, the country still is considered close to achieving the UNAIDS 90-90-90 goals for diagnosis, treatment, and successful HIV viral suppression, that if reached by 2020 could lead to lasting control of the epidemic. On the other hand, the country exemplifies a frustrating plateau -- with more than 1 percent of people there acquiring the virus yearly.

A gap in Botswana's AIDS policy gives one clue to what might be stalling advances against the epidemic there. While offering free antiretroviral treatment to all of its citizens who live with the virus -- preventing transmission as well as illness -- that policy doesn't extend to non-citizens, or as they are also called, immigrants. Seeking to assess the impact of that policy, researchers led by Tafireyi Marukutira, working with the U.S. Centers for Disease Control and Prevention looked at results of an HIV testing campaign and assessments in communities participating in the the Botswana Combination Prevention Project. Of 36,608 people either tested, or with documentation of test results, three percent were non-citizens. Of them 18 percent were living with HIV. And in contrast to citizens, the vast majority of non-citizens did not know their HIV status, or were newly diagnosed, and were not receiving treatment, Marukutira said. For example, while 71 percent of citizens in the study with HIV were accessing antiretroviral treatment, only 29 percent of the non citizens -- or just 61 out of 222 of the immigrants living with HIV -- were on treatment. The obstacles to treatment that they face are significant, according to Marukutira, and include the cost and inconveniences of seeking the medicine, through private practitioners, and by traveling to neighboring Zimbabwe.

Given the progess that Botswana has made, the lack of free antiretroviral treatment for migrants "might be" hindering progress, Marukutira said. His presentation came during a session documenting the multiple risks of HIV infection, illness, and transmission facing immigrants, including exposures in their countries of origin, challenges in transit that can lead to transactional sex, unprotected sex, and sexual violence, and problems in destination countries that can include isolation, exploitation, lack of resources, language barriers and fears of deportation or arrest. To address the needs those conditions raise, Marukutira said, "All Southern African countries need to have a plan."

This article was cross-posted with the permission of Science Speaks. Read the original article.

Related Stories

Botswana 'Treat All' Program Will Move to Universal Treatment With Dolutegravir as First-Line ART
Botswana Within Reach of UNAIDS 90-90-90 Goal

This article was provided by Science Speaks. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections. Visit Science Speaks' website to find out more about their activities and publications.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.